CTMX | CytomX Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.8600 - 0.8950
52 Week Range	0.8330 - 5.85
Beta	0.90
Implied Volatility	380.99%
IV Rank	33.68%
Day's Volume	494,230
Average Volume	788,792
Shares Outstanding	78,258,900
Market Cap	69,650,421
Sector	Healthcare
Industry	Biotechnology
IPO Date	2015-10-08

Valuation
Profitability
Growth
Health
P/E Ratio	5.56
Forward P/E Ratio	N/A
EPS	0.16
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	120
Country	USA
Website	CTMX

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

CTMX's peers: ACHL, ACHV, ALGS, ALLK, ALRN, ANAB, APTO, ARWR, ASMB, ATHA, BOLT, CDTX, CHRS, CKPT, CMRX, CNTB, CNTX, CRBP, SPRO, NLTX, TIL, NXTC, NUVB, CYCC, GLPG, KOD, KPTI, KRON, KZIA, LYRA, MEIP, MTEM, MTNB, NCNA, NKTR, NLSP, OCUL, ONCT, OVID, PRQR, PULM, SLN, SPRC, SRZN, TBPH, WVE, DOMH

*Chart delayed

Analyzing fundamentals for CTMX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is bad and Health is frighteningly weak. For more detailed analysis please see CTMX Fundamentals page.

Watching at CTMX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on CTMX Technicals page.